JP2025507359A - 増強されたｄｎａデンドリマー及びその使用方法 - Google Patents

増強されたｄｎａデンドリマー及びその使用方法 Download PDF

Info

Publication number
JP2025507359A
JP2025507359A JP2024547456A JP2024547456A JP2025507359A JP 2025507359 A JP2025507359 A JP 2025507359A JP 2024547456 A JP2024547456 A JP 2024547456A JP 2024547456 A JP2024547456 A JP 2024547456A JP 2025507359 A JP2025507359 A JP 2025507359A
Authority
JP
Japan
Prior art keywords
composition
polynucleotide
cargo
molecule
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507359A5 (https=
Inventor
ロバート・シー・ゲッツ
ジェニファー・エム・ルーク
サマンサ・ズィー・ブラウン
ケイシー・ジェイ・マセナ
ローリー・エイ・ゲッツ
Original Assignee
コード バイオセラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コード バイオセラピューティクス インコーポレイテッド filed Critical コード バイオセラピューティクス インコーポレイテッド
Publication of JP2025507359A publication Critical patent/JP2025507359A/ja
Publication of JP2025507359A5 publication Critical patent/JP2025507359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024547456A 2022-02-10 2023-02-09 増強されたｄｎａデンドリマー及びその使用方法 Pending JP2025507359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308776P 2022-02-10 2022-02-10
US63/308,776 2022-02-10
PCT/US2023/062270 WO2023154788A2 (en) 2022-02-10 2023-02-09 Enhanced dna dendrimers and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025507359A true JP2025507359A (ja) 2025-03-18
JP2025507359A5 JP2025507359A5 (https=) 2026-02-17

Family

ID=87565106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547456A Pending JP2025507359A (ja) 2022-02-10 2023-02-09 増強されたｄｎａデンドリマー及びその使用方法

Country Status (8)

Country Link
US (1) US20230338557A1 (https=)
EP (1) EP4475891A2 (https=)
JP (1) JP2025507359A (https=)
CN (1) CN119095602A (https=)
AU (1) AU2023217717A1 (https=)
CA (1) CA3243817A1 (https=)
IL (1) IL314724A (https=)
WO (1) WO2023154788A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them
WO2025034978A1 (en) * 2023-08-09 2025-02-13 Code Biotherapeutics, Inc. Enhanced dna dendrimers and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950825B1 (en) * 2013-02-01 2019-09-11 Genisphere, LLC Functionalized dna dendrimers for gene delivery to cells
CN109844134B (zh) * 2016-08-16 2023-05-05 塔驰莱特Ip有限公司 闭合线性dna的生产
KR20220133999A (ko) * 2020-01-31 2022-10-05 타이리스 테라뷰틱스, 에스.엘. 변형된 뉴클레오티드들을 갖는 닫힌 선형 dna
IL314724A (en) * 2022-02-10 2024-10-01 Code Biotherapeutics Inc Improved DNA dendrimers and methods of using them

Also Published As

Publication number Publication date
AU2023217717A1 (en) 2024-08-29
EP4475891A2 (en) 2024-12-18
IL314724A (en) 2024-10-01
CA3243817A1 (en) 2023-08-17
WO2023154788A3 (en) 2023-11-09
WO2023154788A2 (en) 2023-08-17
CN119095602A (zh) 2024-12-06
US20230338557A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
US20260048118A1 (en) Compositions and methods for enhancing triplex and nuclease-based gene editing
US20240084330A1 (en) Compositions and methods for delivering cargo to a target cell
US11779653B2 (en) Multi-armed polyrotaxane platform for protected nucleic acid delivery
CN111770994B (zh) 修饰的cpf1引导rna
Järver et al. Peptide-mediated cell and in vivo delivery of antisense oligonucleotides and siRNA
CN111770757A (zh) 诱导外显子跳读的核酸-多肽组合物和方法
CN111225975A (zh) 抗体介导的cas9向哺乳动物细胞的递送
JP2023515709A (ja) 筋肉特異的プロモーターをコードするａａｖベクターを使用するインビボでの衛星細胞の遺伝子編集
JP2025507359A (ja) 増強されたｄｎａデンドリマー及びその使用方法
WO2024206620A1 (en) Messenger rna encoding casx
JP2008194035A (ja) 高いヌクレアーゼ耐性と優れたｒｎａ干渉効果を発現可能な二本鎖ｒｎａ
WO2024230842A1 (zh) 一种Cas蛋白、其相应的基因编辑系统及应用
WO2024006988A2 (en) Engineered delivery vesicles and uses thereof
KR20240040112A (ko) 방법
JP6795492B2 (ja) ＣＬＣＮ７（ＡＤＯ２ ＣＬＣＮ７依存性）遺伝子変異によって引き起こされる常染色体優性大理石骨病２型（ＡＤＯ２）療法のための短鎖干渉ＲＮＡ（ｓｉＲＮＡ）
WO2025034978A1 (en) Enhanced dna dendrimers and methods of use thereof
US12139713B2 (en) Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell
US20260125688A1 (en) Therapeutic Compounds for Red Blood Cell-Mediated Delivery of an Active Pharmaceutical Ingredient to a Target Cell
JP2025538220A (ja) アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
KR20250009410A (ko) 범용 서프레서 tRNA 및 이의 용도
HK40015136A (en) Nanoliposome-microbubble conjugate and composition for ameliorating or treating hair loss containing the same
HK40032619A (en) Nucleic acid-polypeptide compositions and methods of inducing exon skipping
CA3026112A1 (en) Cpf1 complexes with reduced indel activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260206